Hyalgan

___________________________________________________________________

Goldberg V.M., Buckwalter J.A.

Osteoarthritis and Cartilage 2005; 13, 216-24

Growing clinical evidence supports the notion that, in addition to relieving the symptoms of OA, sodium hyaluronate also modifies the rate of OA disease progression.

These data are consistent with a large body of preclinical data demonstrating equivalent benefits in animal models for a number of HA products, one important issue being the possible impact of HA molecular weight on disease-modifying activities

However, available clinical results form a solid body of evidence to support the ability of one hyaluronate-based product to modify OA disease progression: HYALGAN.

___________________________________________________________________

HYALGAN IS THE MOST CLINICALLY STUDIED VISCOSUPPLEMENTS ON THE MARKET WITH 83 PUBLISHED SCIENTIFIC PAPERS ON CLINICAL TRIALS. SOME OTHER SIMILAR PRODUCTS HAVE AS LITTLE AS 1 CLINICAL TRIAL.

OVER 13,000 PATIENTS INVOLVED IN THE CLINICAL TRIALS

HYALGAN injections give you long-lasting relief of pain or discomfort due to osteoarthritis in the knee, hip or shoulder

All the information in the studies section came from international literature provided by Fidia farmaceutici S.p.A.

Roles of Hyaluronan

The efficacy of Hyalgan

___________________________________________________________________

• Fidia farmaceutici S.p.A.